Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023

Humacyte, Inc.

Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.
Top-line results expected in Q3 2023; BLA submission to FDA planned for Q4 2023.
RMAT designation from FDA received in May 2023 increases chance of priority review.
Ukraine humanitarian program treated 19 trauma patients; data will be included in BLA.
HAV has >1,000 patient-years of experience across multiple indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.